8-K: Curis Announces Second Quarter 2024 Financial Results and Provides Operational Update

Curis reported its second quarter 2024 financial results, highlighted by a net loss of $11.8 million and the European Commission granting Orphan Drug Designation to emavusertib for PCNSL.

Summary

• Curis, Inc. announced its financial results for the second quarter of 2024, reporting a net loss of $11.8 million, or $2.03 per share, compared to a net loss of $12.0 million, or $2.47 per share, for the same period in 2023.
• Revenues for the quarter were $2.5 million, up from $2.2 million in the second quarter of 2023, primarily from royalties on Erivedge sales.
• Research and development expenses increased to $10.3 million for the quarter, up from $10.0 million in the same period last year, due to higher employee-related costs.
• General and administrative expenses also increased to $4.8 million, up from $4.2 million in the second quarter of 2023, also due to higher employee-related costs.
• The company's cash, cash equivalents, and investments totaled $28.4 million as of June 30, 2024, and they expect this to fund operations into the first quarter of 2025.
• Operationally, the European Commission granted Orphan Drug Designation (ODD) to emavusertib for the treatment of primary central nervous system lymphoma (PCNSL).
• Curis expects to have initial data for 15-20 patients with R/R PCNSL by late 2024 and plans to present updated data at the ASH conference in December.
• Preliminary data from the TakeAim Leukemia study showed objective responses in both FLT3m and SFm cohorts of R/R AML patients treated with emavusertib.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments such as the Orphan Drug Designation and promising clinical data, the financial results show a significant net loss and a decreasing cash balance, raising concerns about the company's financial stability and future funding needs. The need for a capital raise is a significant negative.

Positives

• Emavusertib received Orphan Drug Designation from the European Commission for PCNSL, which is a significant regulatory milestone.
• The company is progressing the clinical development of emavusertib with initial data expected for PCNSL patients by late 2024.
• Preliminary data from the TakeAim Leukemia study showed promising objective responses in both FLT3m and SFm cohorts of R/R AML patients.
• Revenues increased to $2.5 million in the second quarter of 2024 compared to $2.2 million in the same period of 2023.
• Other income increased to $0.7 million for the second quarter of 2024, compared to $0.2 million for the same period in 2023.

Negatives

• Curis reported a net loss of $11.8 million for the second quarter of 2024.
• Research and development expenses increased to $10.3 million for the second quarter of 2024.
• General and administrative expenses increased to $4.8 million for the second quarter of 2024.
• The company's cash balance decreased to $28.4 million as of June 30, 2024, from $56.3 million at the end of 2023.

Risks

• Curis may experience adverse results, delays, and/or failures in its drug development programs.
• The company is dependent on the success of emavusertib, and any delays could have a material adverse effect on its business.
• Curis will require substantial additional capital to fund its business and may need to delay or reduce its development programs if it cannot obtain sufficient funding.
• The company faces substantial competition in the biotechnology industry.
• There is a risk that regulatory authorities may delay or restrict the commercialization of Erivedge.
• Curis faces risks related to the transfer and encumbrance of certain royalty payments on Erivedge.

Future Outlook

Curis expects its existing cash, cash equivalents, and investments will enable its planned operations into the first quarter of 2025. The company also anticipates updated clinical data from ongoing studies in late 2024.

Management Comments

• Jonathan Zung, Chief Development Officer, stated that the ODD designation is significant for the development of emavusertib in the EU and shows the high unmet need for this patient population.
• James Dentzer, President and Chief Executive Officer, expressed excitement about advancing a novel treatment for patients with PCNSL and initiating discussions with health authorities to align on a registrational development path for emavusertib in PCNSL.

Industry Context

The announcement highlights Curis's progress in developing emavusertib, an IRAK4 inhibitor, for hematologic malignancies. The Orphan Drug Designation for PCNSL underscores the unmet need in this area and positions Curis to potentially address a niche market. The company's focus on both lymphoma and leukemia aligns with broader trends in oncology drug development.

Comparison to Industry Standards

• Curis's reported net loss of $11.8 million for the quarter is within the range of other clinical-stage biotech companies, but the cash burn rate is a concern.
• The objective response rates observed in the TakeAim Leukemia study are promising compared to historical data for R/R AML patients, but further data is needed to confirm these results.
• The granting of Orphan Drug Designation by the European Commission is a positive development, similar to other companies that have received ODD for rare diseases, which can lead to market exclusivity and faster regulatory pathways.
• Companies like Agios Pharmaceuticals and Kura Oncology are also developing targeted therapies for hematologic malignancies, and Curis's progress will be closely watched in comparison to these competitors.
• The company's cash runway into the first quarter of 2025 is shorter than some peers, which typically aim for at least 12 months of funding, indicating a potential need for additional capital.

Stakeholder Impact

• Shareholders may be concerned about the company's net loss and decreasing cash balance.
• Employees may be impacted by potential delays or reductions in development programs if the company cannot secure additional funding.
• Patients with PCNSL and AML may benefit from the development of emavusertib if it proves to be effective and safe.
• Creditors may be concerned about the company's ability to repay its debts if it does not secure additional funding.

Next Steps

• Curis will continue the clinical development of emavusertib.
• The company expects to have initial data for 15-20 patients with R/R PCNSL by late 2024.
• Curis plans to present updated data at the ASH conference in December.
• The company will host the 3rd Annual Symposium on IRAK-4 in cancer on September 26, 2024.
• Curis will continue discussions with health authorities to align on a registrational development path for emavusertib in PCNSL.

Key Dates

Keywords

emavusertib, IRAK4 inhibitor, PCNSL, AML, Orphan Drug Designation, TakeAim Lymphoma, TakeAim Leukemia, FLT3m, SFm, clinical trials, biotechnology, financial results